Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model

Translational Oncology

Volumn 7, Issue 3, 2014, Pages 368-376

  Yu, Hyun Kyung ^a,b   Lee, Ho Jeong ^c   Yun, Seok Joong ^d   Lee, Sun Joo ^e   Langley, Robert R ^c   Yoon, Yeup ^a   Yi, Lee S H ^b   Bae, Duk Soo ^f   Kim, Jang Seong ^g   Kim, Sun Jin ^c  

^a Mogam Biotechnology Research Institute   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Chungbuk National University College of Medicine   (South Korea)

^e Konkuk University Hospital   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84983051314     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.04.005     Document Type: Article

References (43)

1. Jemal, A, Siegel, R, Xu, J, Ward, E, Cancer statistics, 2010. CA Cancer J Clin 60 (2010), 277–300.
2. Kumaran, GC, Jayson, GC, Clamp, AR, Antiangiogenic drugs in ovarian cancer. Br J Cancer 100 (2009), 1–7.
3. Cannistra, SA, Cancer of the ovary. N Engl J Med 329 (1993), 1550–1559.
4. du Bois, A, Lück, HJ, Meier, W, Adams, HP, Möbus, V, Costa, S, Bauknecht, T, Richter, B, Warm, M, Schroder, W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (2003), 1320–1329.
5. Fidler, IJ, Hart, IR, Biological diversity in metastatic neoplasms: origins and implications. Science 217 (1982), 998–1003.
6. McGuire, WP, Hoskins, WJ, Brady, MF, Kucera, PR, Partridge, EE, Look, KY, Clarke-Pearson, DL, Davidson, M, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996), 1–6.
7. Bookman, MA, McGuire, WP III, Kilpatrick, D, Keenan, E, Hogan, WM, Johnson, SW, O'Dwyer, P, Rowinsky, E, Gallion, HH, Ozols, RF, Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14 (1996), 1895–1902.
8. Vaughan, S, Coward, JI, Bast, RC Jr., Berchuck, A, Berek, JS, Brenton, JD, Coukos, G, Crum, CC, Drapkin, R, Etemadmoghadam, D, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11 (2011), 719–725.
9. Fidler, IJ, The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3 (2003), 453–458.
10. Fidler, IJ, Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87 (1995), 1588–1592.
11. Kim, SJ, Uehara, H, Karashima, T, Shepherd, DL, Killion, JJ, Fidler, IJ, Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9 (2003), 1200–1210.
12. Folkman, J, Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971), 1182–1186.
13. Wenham, RM, Ovarian cancer: a bright future. Cancer Control 18 (2011), 4–5.
14. Cao, Y, Cao, R, Veitonmaki, N, Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents 2 (2002), 667–681.
15. O'Reilly, MS, Holmgren, L, Shing, Y, Chen, C, Rosenthal, RA, Moses, M, Lane, WS, Cao, Y, Sage, EH, Folkman, J, Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994), 315–328.
16. Kurup, A, Lin, CW, Murry, DJ, Dobrolecki, L, Estes, D, Yiannoutsos, CT, Mariano, L, Sidor, C, Hickey, R, Hanna, N, Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 17 (2006), 97–103.
17. Kim, JS, Chang, JH, Yu, HK, Ahn, JH, Yum, JS, Lee, SK, Jung, KH, Park, DH, Yoon, Y, Byun, SM, et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 278 (2003), 29000–29008.
18. Kim, JS, Yu, HK, Ahn, JH, Lee, HJ, Hong, SW, Jung, KH, Chang, SI, Hong, YK, Joe, YA, Byun, SM, et al. Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases. Biochem Biophys Res Commun 313 (2004), 534–540.
19. Lee, HJ, Yu, HK, Papadopoulos, JN, Kim, SW, He, J, Park, YK, Yoon, Y, Kim, JS, Kim, SJ, Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model. Neoplasia 14 (2012), 335–343.
20. Huang, S, Van Arsdall, M, Tedjarati, S, McCarty, M, Wu, W, Langley, R, Fidler, IJ, Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94 (2002), 1134–1142.
21. Kang, KY, Kim, SG, Kim, WK, You, HK, Kim, YJ, Lee, JH, Jung, KH, Kim, CW, Purification and characterization of a recombinant anti-angiogenic kringle fragment expressed in Escherichia coli: Purification and characterization of a tri-kringle fragment from human apolipoprotein (a) (kringle IV (9)–kringle IV (10)–kringle V). Protein Expr Purif 45 (2006), 216–225.
22. Thaker, PH, Yazici, S, Nilsson, MB, Yokoi, K, Tsan, RZ, He, J, Kim, SJ, Fidler, IJ, Sood, AK, Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 11 (2005), 4923–4933.
23. Bruns, CJ, Solorzano, CC, Harbison, MT, Ozawa, S, Tsan, R, Fan, D, Abbruzzese, J, Traxler, P, Buchdunger, E, Radinsky, R, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60 (2000), 2926–2935.
24. Jeong, SJ, Shin, HJ, Kim, SJ, Ha, GH, Cho, BI, Baek, KH, Kim, CM, Lee, CW, Transcriptional abnormality of the hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis. Cancer Res 64 (2004), 8666–8673.
25. Lu, C, Kamat, AA, Lin, YG, Merritt, WM, Landen, CN, Kim, TJ, Spannuth, W, Arumugam, T, Han, LY, Jennings, NB, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13 (2007), 4209–4217.
26. Baker, CH, Kedar, D, McCarty, MF, Tsan, R, Weber, KL, Bucana, CD, Fidler, IJ, Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 161 (2002), 929–938.
27. Oltval, ZN, Milliman, CL, Korsmeyer, SJ, Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993), 609–619.
28. Ramakrishnan, S, Subramanian, IV, Yokoyama, Y, Geller, M, Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8 (2005), 169–182.
29. Masoumi Moghaddam, S, Amini, A, Morris, DL, Pourgholami, MH, Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 31 (2012), 143–162.
30. Teoh, D, Secord, AA, Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int J Gynecol Cancer 22 (2012), 348–359.
31. Hurwitz, H, Fehrenbacher, L, Novotny, W, Cartwright, T, Hainsworth, J, Heim, W, Berlin, J, Baron, A, Griffing, S, Holmgren, E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
32. Raja, FA, Chopra, N, Ledermann, JA, Optimal first-line treatment in ovarian cancer. Ann Oncol 23:Suppl. 10 (2012), x118–x127.
33. Giantonio, BJ, Catalano, PJ, Meropol, NJ, O'Dwyer, PJ, Mitchell, EP, Alberts, SR, Schwartz, MA, Benson, AB III, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007), 1539–1544.
34. Okines, A, Cunningham, D, Current perspective: bevacizumab in colorectal cancer—a time for reappraisal?. Eur J Cancer 45 (2009), 2452–2461.
35. Relf, M, LeJeune, S, Scott, PA, Fox, S, Smith, K, Leek, R, Moghaddam, A, Whitehouse, R, Bicknell, R, Harris, AL, Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57 (1997), 963–969.
36. Baluk, P, Hashizume, H, McDonald, DM, Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15 (2005), 102–111.
37. Jain, RK, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005), 58–62.
38. Yoneda, J, Kuniyasu, H, Crispens, MA, Price, JE, Bucana, CD, Fidler, IJ, Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90 (1998), 447–454.
39. Langley, RR, Ramirez, KM, Tsan, RZ, Van Arsdall, M, Nilsson, MB, Fidler, IJ, Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 63 (2003), 2971–2976.
40. Ribatti, D, Nico, B, Vacca, A, Roncali, L, Dammacco, F, Endothelial cell heterogeneity and organ specificity. J Hematother Stem Cell Res 11 (2002), 81–90.
41. Folkman, J, Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 (2007), 273–286.
42. Perri, SR, Nalbantoglu, J, Annabi, B, Koty, Z, Lejeune, L, Francois, M, Di Falco, MR, Béliveau, R, Galipeau, J, Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res 65 (2005), 8359–8365.
43. Perri, SR, Martineau, D, Francois, M, Lejeune, L, Bisson, L, Durocher, Y, Galipeau, J, Plasminogen kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. Mol Cancer Ther 6 (2007), 441–449.